Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin "PEGASUS"

Completed

Phase 3 Results

Summary of Purpose

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 18 December 2015.

1 Oct 2010 9 Jul 2010 1 Dec 2014 1 Dec 2014 1 Dec 2015 4 Nov 2015
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • AstraZeneca Clinical Study Information

    800-236-9933